Share Name Share Symbol Market Type Share ISIN Share Description
Tarsus Group Plc LSE:TRS London Ordinary Share JE00B3DG9318 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 424.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
424.00 425.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 99.73 16.53 9.40 45.1 521
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 424.00 GBX

Tarsus (TRS) Latest News

Real-Time news about Tarsus Group Plc (London Stock Exchange): 0 recent articles
More Tarsus News
Tarsus Investors    Tarsus Takeover Rumours

Tarsus (TRS) Discussions and Chat

Tarsus Forums and Chat

Date Time Title Posts
25/5/201917:36Tarsus - Exhibition Maestro of the Unusual381
24/8/200615:22Tarsus: Charts & Fundamentals111
15/11/200409:14Tarsus moves forward8
05/3/200409:55Tarsus Breaking out8
09/9/200210:48Targus and Parity collaborative agreement1

Add a New Thread

Tarsus (TRS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tarsus trades in real-time

Tarsus (TRS) Top Chat Posts

Tarsus Daily Update: Tarsus Group Plc is listed in the Media sector of the London Stock Exchange with ticker TRS. The last closing price for Tarsus was 424p.
Tarsus Group Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 0p while the 1 year low share price is currently 0p.
There are currently 122,940,596 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Tarsus Group Plc is £521,268,127.04.
vprt: Yieldsearch / galeforce1: Yes, and in addition I believe John Lee holds (most of?) the following: VP, DJAN, TFW, NICL, TON. And others. TET is his #1 holding by size. He topped up CTR, CTG, and AIR early this year (steady, low profile, divi-paying smallcaps trading at low valuations), in addition to wisely building his large TRS stake. He has been reducing PZC despite his own long-standing very close association. (This is mostly from the 2 Feb column). More recently he talked up CTR by pointing out its, to him, mysteriously low valuation. Like you, galeforce1, I hold several of these and keep an eye on what he does. I actually also had the genuine pleasure of having a good chat with him at/after an AGM, which only a handful of people attended, a couple of years ago. (I took the opportunity to thank him for bringing my attention to TET before it took off).
mpjsb1: Re trading somewhat above the bid price remember there's a 7.7p dividend to be paid also. Be nice if someone else expressed an interest but I'd be surprised. Having said that, I think it went xd yesterday so scrub the previous comment!
felix99: its trading above the bid price so presumably a few traders/ hedgies punting that someone else might enter the bidding fray at a higher price
macc2: Reply to my question about withholding tax from TRS. There is indeed an automatic DWT chargeable on all payments. However, if the broker is in the UK the broker would usually register their UK residency with the Registrar and DWT would not be applied - the dividend would be received gross. However it is up to Barclays to do this. So I have messaged Barclays and they are investigating. The strange thing is that they did pay the July 17 dividend payment gross - without any DWT. So presumably they already have the correct registration with the Registrar????
battlebus2: Notification of Transaction by Director Tarsus announces that it was notified today that on 4 August 2015, a SIPP managed on behalf of Douglas Emslie, Group Managing Director, purchased 3,167 ordinary shares of 5p each ("Shares") of the Company at a price of 219p per share. Douglas Emslie's beneficial interest in Tarsus Shares now totals 1,119,220 Shares, representing approximately 1.1 per cent of the issued ordinary share capital of the Company.
battlebus2: Results out... Financial highlights Financial highlights - six months to 30 June ----------------------------------------------------- 2015 2014 2013 ----------------------------- ------ ------ ------ Revenue (GBP'm) 34.0 23.1 26.0 ----------------------------- ------ ------ ------ Adjusted profit before tax* (GBP'm) 5.5 3.0 3.9 ----------------------------- ------ ------ ------ Profit/ (loss) before tax (GBP'm) (1.9) 0.3 0.8 ----------------------------- ------ ------ ------ Adjusted EPS* (p) 3.4 1.5 2.6 ----------------------------- ------ ------ ------ EPS (p) (3.0) (1.1) (0.9) ----------------------------- ------ ------ ------ Operating Cash Flow (GBP'm) 9.5 1.9 8.9 ----------------------------- ------ ------ ------ Interim dividend per share (p) 2.5 2.4 2.3 ----------------------------- ------ ------ ------ -- Sector leading organic revenue up 14% on 2014 as adjusted for biennial exhibitions and acquisitions clearly demonstrates delivery of our Quickening the Pace Strategy -- Record adjusted profit before tax* and adjusted EPS up 39% and 31% respectively over the biennial cycle -- Interim dividend up 4% to 2.5p (2014: 2.4p) Operational highlights -- Strong performance from Emerging Markets o Asansor and Komatek (Turkey) performed well -- Visitor growth across portfolio of 9% -- Launches of two brand replications in Mexico - GESS and Industrial Print Expo Strategic highlights -- Strategic repositioning of portfolio complete o Disposal of French business (July 2015) -- Acquisition of PAINWeek in US adding final pillar to the Group's preventative medicine portfolio -- Acquisition of AMB doubles South East Asia portfolio -- Banking facilities increased to GBP75m and extended to 2020 Outlook -- Forward bookings currently 15% ahead of 2014 (adjusted for biennial exhibitions) -- Promising outlook for larger events in second half, including Labelexpo Europe and Dubai Airshow -- Turkey and Medical divisions in line with expectations -- Group remains confident of delivering a strong performance in 2015 Douglas Emslie, Group Managing Director, said: "Our record trading performance in the first half was very encouraging and we also made further strategic progress with our replications in Emerging Markets. The investment in our portfolio has resulted in sector leading organic revenue and visitor growth. "The execution of our strategy gathered pace recently with acquisitions of PAINWeek and AMB and the agreement to dispose of our French business. "Revenues for the year as a whole are heavily second-half weighted owing to the timing of the Group's larger exhibitions. Bookings overall are 15% ahead adjusting for biennials. Prospects for our two largest events in the second half - Labelexpo Europe and the Dubai Airshow - are encouraging. The Group is increasingly confident of delivering a strong result for the year as a whole."
battlebus2: AMB Group Joint Venture - Building Scale in South East Asia Tarsus Group plc (LSE: TRS, "Tarsus" or the "Group"), the international business-to-business media group, today announces that it has further strengthened its portfolio and growth prospects in South East Asia by acquiring 50% of the AMB Group via a joint venture vehicle AMB Tarsus Exhibitions Sdn. Bhd. ("AMBT") from Andrew Siow and Richard Yew (the "Vendors") (the "Acquisition"). Established in 1996, the AMB Group is a major South-East Asian exhibition organiser with a major presence in Myanmar and Cambodia and a growing business in the region. It has built up a portfolio of market leading exhibitions and conferences in some of Tarsus' key strategic sectors with the largest focused on building, infrastructure, automotive and food processing. AMB Group has enjoyed strong growth in recent years, driven by the establishment of leading events in Myanmar and Cambodia - MyanFood and Cambuild respectively. The partnership adds significant scale and presence across South East Asia, building on Tarsus' existing successful assets in Indonesia - PT Infrastructure Asia and the replication of two Tarsus brands, GESS Indonesia and Table and Home Indonesia. Tarsus intends to scale up AMBT's existing events and launch new exhibitions in its existing markets. As part of its accelerated replication program Tarsus also expects to be able to introduce a number of its leading brands into AMBT's markets of Malaysia, Myanmar and Cambodia. Tarsus will also assist AMBT to access Indonesia by utilising the Group's existing infrastructure in that market. Acquisition highlights -- The Vendors, who have over 30 years' experience in the exhibition industry, will continue to manage the business after acquisition. -- The acquisition of 50% of AMBT is for an estimated payment of $13 million (approx. GBP9 million) in cash of which $4.1 million (approx. GBP2.6 million) is payable on completion of the Acquisition with a further $4.1 million payable in January 2016 and deferred payments linked to the performance of the business up to the end of 2017. The total consideration for the initial 50% is capped at $20 million (approx. GBP12.8 million). -- For the year ended 28 February 2015, AMB Group recorded unaudited profit before tax of approximately $2.2 million (approx. GBP1.4 million) and unaudited gross assets of $2.9 million (GBP1.8 million). -- The consideration will be met from existing financial resources. To provide additional headroom the Group has increased its bank facilities to GBP75m (from GBP60m) and extended the term of the facilities out to July 2020. The other commercial terms of the bank facilities are unchanged. -- The Acquisition is expected to be earnings accretive in the financial year ending 31 December 2015 and thereafter. -- There is a put and call option in respect of the Vendor's remaining 50% stake in AMBT (the "Remaining Stake"). The Vendors will be permitted to sell the Remaining Stake to Tarsus in the event of a sale of at least 50.1% of Tarsus ordinary shares of 5p each collectively held (either directly or beneficially) by both Neville Buch, Chairman and Douglas Emslie, Group Managing Director as at the date of completion. In this circumstance the Vendors may sell their Remaining Stake to Tarsus for a maximum consideration of $25m (approx. GBP16.1 million) in cash determined in reference to the profit of AMBT in the financial year (31 December) immediately preceding exercise of the option. Douglas Emslie, Tarsus Group Managing Director said: "AMBT is an excellent strategic acquisition and allows Tarsus to build scale in South East Asia with an entrepreneurial partner. Many of the ASEAN economies are growing strongly and the AMBT joint venture will offer us first-mover advantage in some key sectors in these exciting markets. "I have known Andrew Siow for over 20 years and he and Richard have an excellent track record in launching and developing events in the region. Their expertise will add significant strength and depth to the Group's operations in South East Asia. We expect there to be compelling opportunities to replicate Tarsus' leading brands into AMBT's geographic footprint." Tarsus intends to announce its results for the six months ended 30 June 2015 on 29 July 2015.
larusso1: I've been looking at TRS over the last few months and all the news and fundamentals look good. I'm pretty new to investing, so can I ask what you mean by "fall out of the index for liquidity in June" ? I presume this is whats casuing the dip at the moment? Thanks
battlebus2: More acquisitions and placing of 5.2% of the share capital. I don't hold.. Tarsus Group plc (LSE: TRS, "Tarsus" or the "Company"), the international business-to-business media group, is pleased to announce the following acquisitions in two of its key markets. The Company has agreed to acquire 100% of the assets of HealthScienceMedia Inc. ("HSM") in the US and 60% of SADA Uzmanlik Fuarlari A.S. ("SADA") in Turkey (together the "Acquisitions"). The Company has also today announced a placing of 5.0m shares representing approximately 5.2 per cent of the Company's existing issued share capital (the "Placing"). The Acquisitions and the Placing are not inter-conditional and full details of the Placing are contained in a separate announcement released today. CARDIO The principal asset being acquired from HSM is the Cardiometabolic Health Congress ("CMHC" or "Cardio"), the largest US event focused on the cardiometabolic field. It is an annual congress which began in 2006 and is held over three days each October in Boston. CMHC's 2012 delegates comprised approximately 1,500 practising clinicians. Healthcare providers and physicians increasingly understand that integrated management of all aspects of cardiometabolic risk (including obesity and type 2 diabetes) is an important way to deal with this rapidly growing problem area and this field of medicine is attracting significant pharmaceutical company investment. Cardio is complementary to Tarsus' existing medical business and provides an established audience for the division's recently launched new mainstream product, the Metabolic Medicine Institute. We also believe there will be a number of possible synergies with the Group's existing medical division. HSM is owned by Alex Teperman, who will remain with the business on a consultancy basis. The unaudited profits attributable to the assets being acquired in the twelve months to 31 December 2012 were US$2.0m (approximately £1.2m) on revenues of US$3.5m (approximately £2.1m) and the gross assets being acquired amount to approximately US$0.5m (approximately £0.3m). Tarsus is acquiring the assets of HSM for $14 million (approximately £8.5m) of which $10m (approximately £6.1m) is payable in cash on completion with the balance payable in two equal cash payments after the 2014 and 2015 Cardio events respectively. KOMATEK Established in 1967 and based in Ankara, SADA organises a single event - Komatek - which was first held in 1991. This biennial (odd years) show is Turkey's largest trade exhibition for construction equipment and related products. The last edition was held in May 2013 at the Ataturk Centre in Ankara with combined indoor and outdoor net space of 53,200m2. Over 400 exhibitor companies were present and visitor numbers, at approximately 35,000, were 9% higher than the 2011 event. Komatek is the largest construction equipment exhibition in Turkey and one of the largest events in Europe. With US$1.0 trillion worth of major construction and investment projects expected to be completed in Turkey between now and 2023, the Group expects strong growth in Turkey's construction market over that timeframe. SADA's management team has delivered strong performance to date and will continue to run the business post-acquisition. The exhibition also enjoys support from a key industry association. The purchase of Komatek further strengthens Tarsus' position in the Turkish market and adds scale to our Ankara operations. The city's importance as an exhibition centre is expected to increase when the new Akyurt venue has been built, which is anticipated in 2015. Additionally, the Group believes there are synergies with Tarsus's CYF business, which owns Yapi Decoor (a building interiors event) and the Group's infrastructure event in Indonesia. Unaudited revenues at Komatek in 2013 were TL3.3m (approximately £0.9m). Tarsus will pay an initial TL5.0m (approximately £1.4m) on completion and two additional payments contingent on the profit performance of the 2015 and 2017 events. The total consideration for 60% of SADA is capped at TL20.0m (approximately £5.6m). The Acquisitions and the Placing together are expected to be earnings enhancing in the year ending 31 December 2014.
woodcutter: b2 very strong but my guess is the the share price is already up with events. Indeed we might see some profit taking this morning into such a strong statement so my guess would be a slight drop in share price toward the end of the day creating a possible buying opportunity. But as always i could be wrong. Mm's to mark up price first thing and sellers to come in then share price will drift down is my guess. The only thing i din't like was the operating cash flow was skewed by the amount of trade payables Woody
Tarsus share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210624 07:16:18